Breast cancer remains the second most common cancer in women, and is one of the few cancer sites for which incidence rates continue to rise. In addition, despite improvements in breast cancer survival, racial disparities in mortality remain pervasive. These mortality disparities have been widening over the last two decades, with the odds of dying from breast cancer for Black vs. White women increasing from 1.27 in 1984 to 1.85 in 1999. This racial inequality in breast cancer outcomes is cast on the backdrop of an obesity epidemic. We have assembled an experienced multidisciplinary team from Georgetown University, Einstein College of Medicine, Erasmus University, and RAND to use two established models (SPECTRUM and MISCAN) to develop a mini """"""""base case"""""""" with common parameters to simulate how obesity (defined as BMI >30) interacts with risk, screening outcomes, and treatment effectiveness to effect trends in overall and race specific US breast cancer incidence and mortality from 1975 to 2015. We will also project results to 2025 to capture the lag time in effects of obesity (and screening). We have selected obesity as a key modifiable risk factor to be examined since it has been identified as a proximate target for change to achieve the Healthy People 2010 targets, disproportionately effects Black women, and impacts breast cancer incidence and mortality through several mechanisms with potentially competing effects. As secondary goals, we will also examine how screening policies and treatment improvements are likely to impact future differences in rates of breast cancer between Black and White women. Our objectives will be accomplished in three phases: In the first phase, we will focus on developing the common data inputs needed to address our research questions. In phase 2, we will use the models to synthesize the data and conduct analyses. Finally, in Phase 3, we will use the results to inform policy and practice relevant discussions and make the models available to others to address emerging research questions. Throughout, we will also collaborate with other CISNET modeling groups. By working together with 2 models, we can achieve important economies of scale, test the impact of model structure on results, provide a range of plausible projections, and contribute to a better understanding of the science of modeling. Overall, the information generated by these models will provide a framework to inform policy debates about equity in care and how to best achieve targeted reductions in breast cancer morbidity and mortality for all US women.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA088283-09
Application #
7681674
Study Section
Special Emphasis Panel (ZCA1-SRRB-K (M1))
Program Officer
Stedman, Margaret R
Project Start
2000-09-01
Project End
2011-08-31
Budget Start
2009-09-01
Budget End
2011-08-31
Support Year
9
Fiscal Year
2009
Total Cost
$441,454
Indirect Cost
Name
Georgetown University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Alagoz, Oguzhan; Berry, Donald A; de Koning, Harry J et al. (2018) Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models. Med Decis Making 38:3S-8S
Mandelblatt, Jeanne S; Near, Aimee M; Miglioretti, Diana L et al. (2018) Common Model Inputs Used in CISNET Collaborative Breast Cancer Modeling. Med Decis Making 38:9S-23S
Schechter, Clyde B; Near, Aimee M; Jayasekera, Jinani et al. (2018) Structure, Function, and Applications of the Georgetown-Einstein (GE) Breast Cancer Simulation Model. Med Decis Making 38:66S-77S
Munoz, Diego F; Plevritis, Sylvia K (2018) Estimating Breast Cancer Survival by Molecular Subtype in the Absence of Screening and Adjuvant Treatment. Med Decis Making 38:32S-43S
van Ravesteyn, Nicolien T; Stout, Natasha K; Schechter, Clyde B et al. (2015) Benefits and harms of mammography screening after age 74 years: model estimates of overdiagnosis. J Natl Cancer Inst 107:
van Ravesteyn, Nicolien T; van Lier, Lisanne; Schechter, Clyde B et al. (2015) Transition from film to digital mammography: impact for breast cancer screening through the national breast and cervical cancer early detection program. Am J Prev Med 48:535-42
Bensink, Mark E; Ramsey, Scott D; Battaglia, Tracy et al. (2014) Costs and outcomes evaluation of patient navigation after abnormal cancer screening: evidence from the Patient Navigation Research Program. Cancer 120:570-8
Lansdorp-Vogelaar, Iris; Gulati, Roman; Mariotto, Angela B et al. (2014) Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. Ann Intern Med 161:104-12
Mandelblatt, Jeanne S; Tosteson, Anna N A; van Ravesteyn, Nicolien T (2013) Costs, evidence, and value in the Medicare program: the challenges of technology innovation in breast cancer prevention and control. JAMA Intern Med 173:227-8
Graham, Amanda L; Chang, Yaojen; Fang, Ye et al. (2013) Cost-effectiveness of internet and telephone treatment for smoking cessation: an economic evaluation of The iQUITT Study. Tob Control 22:e11

Showing the most recent 10 out of 35 publications